Are Telehealth Stocks Set to Tumble in 2026?

Medicare telehealth reimbursement flexibilities enacted early in the pandemic are set to expire on Jan. 31, 2026, meaning only telehealth delivered from healthcare facilities, in rural areas, or for virtual mental health will be reimbursed; routine at-home telemedicine in nonrural areas will no longer be covered. The change threatens demand for pure-play Teladoc (TDOC), which remains unprofitable, has slow revenue growth and ongoing reimbursement issues for BetterHelp, while Doximity (DOCS) is less exposed given diversified subscription and pharma-marketing revenue and ~80% U.S. physician penetration—but its growth has slowed and investor expectations may remain pressured, leaving both names vulnerable in 2026.

Analysis

Market structure: The CMS rollback (effective Jan 31, 2026) immediately shifts reimbursement away from home-based telehealth for non‑rural Medicare beneficiaries, favoring in‑person providers, urgent care chains and facility‑based telehealth vendors that can bill originating site fees. Pure‑play telehealth (TDOC) is the clear loser; multi‑product platforms with ad/subscription or pharma‑marketing revenue (DOCS) are insulated but face slower growth. I estimate a plausible near‑term 10–25% reduction in Medicare telehealth visit volume, translating to a single‑digit percent revenue hit for diversified players and a larger proportional hit for TDOC given higher Medicare mix.

Risk assessment: Tail risks include Congressional extension of waivers (positive for TDOC) or aggressive payer contract nonrenewals (negative); either could move share prices >30% within 90 days. Immediate risk window: days around Jan 31; short term: Q1 2026 results and renewals (6–12 weeks); long term: secular employer/commercial adoption and international expansion (3–12 months). Hidden dependencies: commercial employer contracts, BetterHelp reimbursement status, and state Medicaid rules which could offset or amplify CMS action. Key catalysts: CMS clarifications in 30 days, major commercial payor announcements, and TDOC Q1 guidance in 6–10 weeks.

Trade implications: Tactical short TDOC (size 1.5–3% net portfolio) into Jan 31 event; pair with a smaller long DOCS (0.5–1%) to play relative resilience in advertising/subscription revenues. Use options: buy 3‑month at‑the‑money TDOC puts or 6‑month 25‑delta puts to limit capital at risk; set hard stop-loss at 20% adverse move or close on substantive CMS reversal. Rotate proceeds into large-cap hospital operators (e.g., HCA) or diversified health IT with >50% non‑Medicare revenue; expect reallocation within 2–3 weeks and rebalancing after Q1 earnings.

Contrarian angles: The market may overdiscount commercial and international revenue — if TDOC posts >15% YoY international growth and retains employer contracts, downside could be muted and create a mean‑reversion buy at >30% decline. Historical parallels (temporary pandemic telehealth waivers rolled back then partially restored) suggest policy is reversible within one congressional cycle; size shorts accordingly and monitor three leading indicators: CMS guidance, top‑5 payor contract renewals, and BetterHelp reimbursement wins within 90 days.

Key Decisions for Investors

• Establish a tactical short position in TDOC sized 1.5–3% of portfolio within the next 3 trading days ahead of the Jan 31, 2026 CMS change; target profit if TDOC falls 20–35%, stop-loss if TDOC rises 20% from entry.
• Purchase TDOC 3‑month at‑the‑money puts or 6‑month 25‑delta puts (size equivalent to 1% portfolio exposure) to express directional downside while capping capital at risk; roll or close after Q1 2026 earnings if no policy reversal.
• Implement a pair trade: go long DOCS 0.5–1% vs short TDOC 1–2% to capture relative stability from DOCS's advertising/subscription cash flows; exit or rebalance after commercial payor announcements or if DOCS shows <5% QoQ revenue contraction.
• Rotate 1–2% of portfolio into defensive healthcare operators (e.g., HCA) or diversified health‑IT vendors with <20% Medicare revenue within 2–3 weeks, expecting a 6–12 month rehypothecation of in‑person care demand; take profits if these names outperform sector by >10%.
• Monitor three specific catalysts over the next 90 days before changing sizing: (1) CMS published clarifications/waiver extensions, (2) top‑5 commercial payor contract renewals mentioning telehealth reimbursement, and (3) BetterHelp third‑party reimbursement wins/losses; adjust positions within 48 hours of any of these events.